The Searle Company Limited (PSX: SEARL) Monday announced that it has successfully obtained registration of Denosumab injections 120mg and 60mg (biosimilar drugs) from the Drug Regulatory Authority of Pakistan.
The company, being the product registration holder in Pakistan, has been granted rights under a License Agreement by Mabwell Pharmaceuticals, China (the manufacturer) to market and sell these biosimilar drugs in Pakistan. Denosumab is a monoclonal antibody and to be used for the management of osteoporosis (60mg) and oncology care (120mg), the company announced in a notice to the Pakistan Stock Exchange (PSX).
Read More: Sazgar Engineering Posts Profit of Rs. 16 Billion in FY25
“We are pleased to inform that the Company is now preparing for the commercial launch of Denosumab injections in Pakistan, marking a significant milestone in expanding its product portfolio,” the notice said.
This development reflects the company’s commitment to enhancing its product offerings and strengthening its business, thereby improving the quality of its earnings and creating greater value for shareholders, it added.
